

SAS:gte 02/26/04 5759-67874
PATENT

Express Mail Label No. EV331581564US
Date of Deposit: February 26, 2004
Attorney's Matter No. 5759-67874

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Hare et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: USES OF TRANSPORT PROTEINS

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5759-67874

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV331581564US in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed

February 26, 2004

MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/747,772, which was filed December 20, 2000, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application. Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.

SAS:gte 02/26/04 5759-67874
PATENT

Express Mail Label No. EV331581564US
Date of Deposit: February 26, 2004
Attorney's Matter No. 5759-67874

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this Information Disclosure Statement is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	5759-67874
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	O'Hare
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,747,641	5 May 1998	Frankel et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 97/05265	13 Feb. 1997	WIPO
		WO 98/32866	30 July 1998	WIPO
		WO 98/42742	1 Oct. 1998	WIPO

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Dalton et al., <i>J. Clin. Oncol.</i> 7:415, 1989
		Dilber et al.: "Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22" - <i>Gene Therapy</i> , 6(1):12-21, 1999
		Elliott and O'Hare: "Intercellular Trafficking of VP22-GFP fusion proteins," <i>Gene Therapy</i> , 6, 149-151, 1999.
		Fernandez et al., <i>Nature Biotech.</i> 16:418, 1998
		Murphy et al., <i>Gene Therapy</i> 6:4, 1999
		Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," 1995

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.